Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBIT (2023 - 2025)

Historic EBIT for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$33.0 million.

  • Monte Rosa Therapeutics' EBIT fell 2430.73% to -$33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 10659.87%. This contributed to the annual value of -$81.1 million for FY2024, which is 4340.14% up from last year.
  • Monte Rosa Therapeutics' EBIT amounted to -$33.0 million in Q3 2025, which was down 2430.73% from -$15.6 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year EBIT high stood at $44.0 million for Q1 2025, and its period low was -$37.2 million during Q2 2023.
  • Moreover, its 3-year median value for EBIT was -$33.0 million (2025), whereas its average is -$20.8 million.
  • The largest annual percentage gain for Monte Rosa Therapeutics' EBIT in the last 5 years was 22600.8% (2025), contrasted with its biggest fall of 2430.73% (2025).
  • Monte Rosa Therapeutics' EBIT (Quarter) stood at -$34.9 million in 2023, then surged by 137.3% to $13.0 million in 2024, then tumbled by 353.58% to -$33.0 million in 2025.
  • Its EBIT stands at -$33.0 million for Q3 2025, versus -$15.6 million for Q2 2025 and $44.0 million for Q1 2025.